Abstract
The bcl-2 proto-oncogene functions as a cell death suppressor, and its expression prolongs cell survival by blocking apoptosis. Data available on the clinical relevance of bcl-2 protein expression in patients with non-small-cell lung cancer (NSCLC) are controversial. We analysed the role of bcl-2 protein expression on 6-year relapse-free survival in 229 patients with stage I-IIIa NSCLC (101 squamous cell carcinomas and 128 adenocarcinomas) subjected to surgery, with curative intent. Immunohistochemical analysis was performed on archival material by using a monoclonal antibody anti-bcl-2 (clone 124). Bcl-2 protein expression, which was detected in 22% of the cases, was significantly related to stage, histology and grading, and was an indicator of clinical outcome. The probability of relapse-free survival at 6 years was longer for patients with bcl-2-positive tumours (74%) than for those with bcl-2-negative tumours (57%) (P=0.02). This finding was mainly evident for the subgroups of patients with stage IIIa tumours (P=0.05), squamous cell carcinoma (P=0.03) or moderately/poorly differentiated tumours (P=0.02). However, multivariate analysis by Weibull’s regression model indicated that bcl-2 protein expression was not an independent prognostic risk factor in patients with curable NSCLC when the information provided by stage was available.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 5 August 1997 / Accepted: 11 December 1997
Rights and permissions
About this article
Cite this article
Silvestrini, R., Costa, A., Lequaglie, C. et al. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Archiv 432, 441–444 (1998). https://doi.org/10.1007/s004280050188
Issue Date:
DOI: https://doi.org/10.1007/s004280050188